© BusinessWire
11.12.2025
ITGR
LISTED
NYSE
Securities Fraud Investigation Into Integer Holdings Corporation (ITGR) Announced – Investors Who Lost Money Urged To Contact Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm
News Preview
Glancy Prongay & Murray LLP, a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Integer Holdings Corporation (“Integer” or the “Company”) (NYSE: ITGR) investors concerning the Company’s possible violations of the federal securities laws.
IF YOU ARE AN INVESTOR WHO LOST MONEY ON...
Themefolio
Profiler
Peergroup
© Globe Newswire
11.12.2025
PCRX
LISTED
TSX
PharmaCorp Enters Letter of Intent for the Acquisition of Pharmacy Files in Western Canada
News Preview
SASKATOON, Saskatchewan, Dec. 11, 2025 (GLOBE NEWSWIRE) -- PHARMACORP RX INC. (“PharmaCorp” or the “Corporation”) (TSXV: PCRX) is pleased to announce that it has entered into a non-binding letter of intent (“LOI”) to acquire from an arm’s length vendor (the “Vendor”) the prescription files, patient records, and related operational data (the “Phar...
Themefolio
Profiler
Peergroup
© ACCESSWIRE
11.12.2025
SKNY
LISTED
CSE
LIR Life Sciences Files Provisional Patent Application for Needle-Free Delivery of GLP/GIP-Based Obesity Therapies
News Preview
VANCOUVER, BC / ACCESS Newswire / December 11, 2025 / LIR Life Sciences Corp. (CSE:SKNY)(Frankfurt:N790, WKN: A41QA9) ("LIR" or the "Company") announces that it has filed a provisional patent application intended to cover a needle-free delivery platform for GLP/GIP[1]-based therapies used in obesity and metabolic disease. LIR fi...
Themefolio
Profiler
Peergroup
Worth to know
20.10.2025
Short Selling Radar
USA, Europe, Asia
Track Short Selling Activities worldwide
Knowing what matters
Short sale statistics, hedge fund activities and much more user-friendly information
© Globe Newswire
11.12.2025
MAIA
LISTED
XASE
MAIA’s Ateganosine Surges Ahead with Breakthrough Momentum as Pivotal Phase 3 Trial Initiates
News Preview
CHICAGO, Dec. 11, 2025 (GLOBE NEWSWIRE) -- Ateganosine (THIO, 6-thio-2'-deoxyguanosine), a first-in-class telomere-targeting therapy under development by MAIA Biotechnology (NYSE American: MAIA), appears to be gaining increasing attention in the oncology community as emerging clinical results continue to surpass expectations in advanced non-small...
Themefolio
Profiler
Peergroup
Swarmalpha i/o · The Event Futures Prediction X
20.10.2025
© PR Newswire
11.12.2025
CVS
LISTED
NYSE
CVS Health offering measles vaccine to South Carolina residents amid the state's current outbreak
News Preview
Unvaccinated residents can receive a measles vaccine at select CVS Pharmacy and MinuteClinic locations across the stateWOONSOCKET, R.I., Dec. 11, 2025 /PRNewswire/ -- As South Carolina public health officials work to stop the spread of measles following the current outbreak in the state, CVS Health® (NYSE:CVS) is offering the measles-mumps-rubella...
Themefolio
Profiler
Peergroup
© Globe Newswire
11.12.2025
AB
LISTED
EURONEXT
AB Science announces new publication on Medrxiv highlighting clinical benefit with masitinib in Amyotrophic Lateral Sclerosis patients prior any complete loss of function
News Preview
PRESS RELEASE...
Themefolio
Profiler
Peergroup
© ACCESSWIRE
11.12.2025
XBIO
LISTED
NASDAQ
Xenetic Biosciences, Inc. Announces Adjournment of 2025 Annual Meeting
News Preview
Adjourns 2025 Annual Meeting of StockholdersUrges Stockholders Who Have Not Voted To Get Votes In FRAMINGHAM, MA / ACCESS Newswire / December 11, 2025 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immuno-oncology technologies addressing difficu...
Themefolio
Profiler
Peergroup
© PR Newswire
11.12.2025
1952
LISTED
HKSE
Everest Medicines Announces Commercialization Service Agreement and License Agreement with Hasten
News Preview
- Accretive Commercialization Services Agreement covering six mature assets across critical care, cardiovascular, and metabolic disease leveraging Everest's existing commercial organization- Exclusive Greater China license to develop and commercialize Lerodalcibep, a novel, small protein-binding, third-generation PCSK9 inhibitor that adds to the...
Themefolio
Profiler
Peergroup
© Globe Newswire
11.12.2025
BIOPOR
LISTED
CPH
Changes to the Executive Management
News Preview
December 11, 2025...
Themefolio
Profiler
Peergroup
© PR Newswire
11.12.2025
ERAS
LISTED
NASDAQ
Platform Technologies Drive $211B Surge in Precision Cancer Treatment
News Preview
Issued on behalf of GT Biopharma, Inc.VANCOUVER, BC, Dec. 11, 2025 /PRNewswire/ -- Equity Insider News Commentary – November's wave of FDA oncology approvals signals the industry's shift toward platform-based precision therapies over broad-spectrum approaches[1]. The global anticancer drug market now values immunotherapies at over 45% of total can...
Themefolio
Profiler
Peergroup
© PR Newswire
11.12.2025
ERAS
LISTED
NASDAQ
Platform Technologies Drive $211B Surge in Precision Cancer Treatment
News Preview
Issued on behalf of GT Biopharma, Inc.VANCOUVER, BC, Dec. 11, 2025 /CNW/ -- Equity Insider News Commentary – November's wave of FDA oncology approvals signals the industry's shift toward platform-based precision therapies over broad-spectrum approaches[1]. The global anticancer drug market now values immunotherapies at over 45% of total cancer dru...
Themefolio
Profiler
Peergroup
© ACCESSWIRE
11.12.2025
EXOZ
LISTED
NASDAQ
eXoZymes Achieves 100× Scale-up of NCT Production Using Exozymes, Demonstrating Near-perfect Feedstock Conversion
News Preview
LOS ANGELES, CALIFORNIA / ACCESS Newswire / December 11, 2025 / Today, eXoZymes Inc. (NASDAQ:EXOZ) ("eXoZymes") - a pioneer of AI-enhanced enzymes that can transform sustainable feedstock into nutraceuticals and new medicines - announced the successful achievement of a 100-fold scale-up of its N-trans-caffeoyltyramine (NCT) production pro...
Themefolio
Profiler
Peergroup
Advertisment
20.10.2025
© BusinessWire
11.12.2025
STAA
LISTED
NASDAQ
STAAR Surgical Sets the Record Straight Regarding its Robust Go-Shop Process
News Preview
STAAR Surgical Company (NASDAQ: STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today issued the following statement to correct misinformation regarding its robust go-shop process to evaluate available alternatives to the pending merger with Alcon (SIX/NYSE: ALC).
Broad...
Themefolio
Profiler
Peergroup
© Newsfile
11.12.2025
HEM
LISTED
TSX
Hemostemix CEO Introduces Conformal Consciousness Hypothesis A = E/(hv)
News Preview
Thomas Smeenk, BA, unveils a proposed conformal invariant, A = E/(hv), explored as a potential bridge between General Relativity, Quantum Mechanics, cosmology, and string theory.Calgary, Alberta--(Newsfile Corp. - December 11, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) the leading autologous (patient's own) stem cell therapy com...
Themefolio
Profiler
Peergroup
© PR Newswire
11.12.2025
ILMN
LISTED
NASDAQ
Illumina and MyOme Strike Collaboration Deal Including Strategic Investment to Support MyOme's Clinical Trial That Could Save U.S. Healthcare $200 Billion Annually
News Preview
Partnership unites Illumina's leading sequencing technology with cutting-edge clinical genomics analyses and AI to advance precision medicine for early detection and prevention. SAN DIEGO and MENLO PARK, Calif., Dec. 11, 2025 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) and MyOme, a leading genomics innovation and risk modeling company, today ann...
Themefolio
Profiler
Peergroup
© EQS Newswire
11.12.2025
SKNY
LISTED
CSE
Ist das die erhoffte Transformation der Adipositasbehandlung? Lir Life Sciences designt neue Vergleichsstudie zu zellpenetrierenden Peptiden in “GLP”/”GIP”-Therapie
News Preview
EQS-Media / 11.12.2025 / 15:10 CET/CEST
Lir Life Sciences Corp. (ISIN: CA50206C1005 | WKN: A41QA9), Lir oder das Unternehmen, freut sich, das Design einer neuen vergleichenden Studie zur Aufnahme von zellpenetrierenden Peptiden in der “GLP”/”GIP”-basierten Adipositastherapie bekannt zu geben. “GLP” (Glukose-abhängiges insulinotropes Polypeptid......
Themefolio
Profiler
Peergroup
© PR Newswire
11.12.2025
ELVN
LISTED
NASDAQ
Enliven Therapeutics Announces New CEO to Drive Next Phase of Development
News Preview
Rick Fair, a seasoned executive with deep experience developing and commercializing hematology products, joins Enliven as Chief Executive Officer Co-Founder Sam Kintz will assume a new position as Head of PipelineBOULDER, Colo., Dec. 11, 2025 /PRNewswire/ -- Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage bioph...
Themefolio
Profiler
Peergroup
© PR Newswire
11.12.2025
VNRX
LISTED
XASE
Volition Solves Liquid Biopsy's "Needle in a Haystack" Problem; Achieves 180-fold (18,000%) Enrichment
News Preview
HENDERSON, Nev., Dec. 11, 2025 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, announces preprint availability of a new manuscript entitled "Direct analysis of transcription factor protected cfDNA in plasma by ChIP-seq: Measurement of altered CTCF binding in cancer is a novel biomarker f...
Themefolio
Profiler
Peergroup
© BusinessWire
11.12.2025
PSNL
LISTED
NASDAQ
New Publication Demonstrates the Importance of NeXT Personal Ultrasensitive Detection of Residual Disease in Lung Cancer
News Preview
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today announced the publication of one of the largest and most comprehensive patient cohorts to date from the landmark TRACERx study, in the journal Cell. The study, titled "Longitudinal ultrasensitive ctDNA monitoring for high-resolution lung cancer risk predic...
Themefolio
Profiler
Peergroup
© Newsfile
11.12.2025
HEM
LISTED
TSX
Hemostemix Grants Stock Options
News Preview
Calgary, Alberta--(Newsfile Corp. - December 11, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") is pleased to announce that in accordance with its stock option plan, it has granted on December 11, 2025, subject to regulatory approval, a total of 963,000 stock options to purchase common shares of Hemo...
Themefolio
Profiler
Peergroup
© PR Newswire
11.12.2025
WWH
LISTED
LSE
Worldwide Healthcare Trust PLC - Net Asset Value(s)
News Preview
WORLDWIDE HEALTHCARE TRUST PLC
LEI: 5493003YBCY4W1IMJU04
NET ASSET VALUE
The estimated un-audited net asset val...
Themefolio
Profiler
Peergroup
© BusinessWire
11.12.2025
BAX
LISTED
NYSE
Baxter Presents Real-World Data at American Society of Health System Pharmacists Meeting Demonstrating Smart Infusion Pump Electronic Medical Record (EMR) Integration May Improve Patient Safety and Nursing Bedside Productivity
News Preview
Baxter International Inc. (NYSE:BAX), an innovative leader in infusion therapies and technologies, today announced data in collaboration with The University of Texas Medical Branch (UTMB Health) demonstrating the positive impact of smart infusion pump integration with hospital electronic medical records (EMRs) on patient safety, clinicians' bedsid...
Themefolio
Profiler
Peergroup
© PR Newswire
11.12.2025
RNAZ
LISTED
NASDAQ
TransCode Therapeutics and Quantum Leap Healthcare Collaborative Launch a Phase 2a dose-expansion trial with TTX-MC138, following positive readouts from TransCode's Phase 1 trial
News Preview
BOSTON, Dec. 11, 2025 /PRNewswire/ -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ) and Quantum Leap Healthcare Collaborative ("Quantum Leap") today announce a new collaboration to evaluate TransCode's lead therapeutic candidate TTX-MC138 as part of the Quantum Leap PRE-I-SPY clinical trial platform....
Themefolio
Profiler
Peergroup
© BusinessWire
11.12.2025
GH
LISTED
NASDAQ
Guardant Health Announces Collaboration with Trial Library to Increase Access to Cancer Clinical Trials Across the U.S.
News Preview
Guardant Health (Nasdaq: GH), a leading precision oncology company, and Trial Library, an AI technology company enabling oncology clinical trials as a care option, today announced a strategic collaboration to increase access to cancer clinical trials in the United States.
The collaboration combines Guardant Health’s suite of cutting-edge precisio...
Themefolio
Profiler
Peergroup
© BusinessWire
11.12.2025
SVRA
LISTED
NASDAQ
Savara Announces European Patent Office (EPO) Intends to Grant a Patent for the Liquid Formulation of MOLBREEVI*
News Preview
Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the EPO notified the Company of its intention to grant a patent application covering the liquid formulation of MOLBREEVI, an orally inhaled recombinant human granulocyte-macrophage colony-stimulating factor (GM...
Themefolio
Profiler
Peergroup
© PR Newswire
11.12.2025
XTNT
LISTED
XASE
Xtant Medical Announces Commercial Launch of its Next-Generation nanOss Strata™ Synthetic Bone Graft
News Preview
nanOss Strata™ is designed to more closely mimic the structure of human bone, increase the graft's surface area, improve osteoconductivity and enhance the stimulation of cellular activityBELGRADE, Mont., Dec. 11, 2025 /PRNewswire/ -- Xtant Medical Holdings, Inc. (NYSE American: XTNT), a medical technology company focused on surgical solutions for...
Themefolio
Profiler
Peergroup
© PR Newswire
11.12.2025
ATOS
LISTED
NASDAQ
Atossa Therapeutics Receives FDA Rare Pediatric Disease Designation for (Z)-Endoxifen for Duchenne Muscular Dystrophy
News Preview
Designation expands (Z)-Endoxifen program into rare pediatric neuromuscular disease and may qualify Atossa for a future Priority Review Voucher upon approvalSEATTLE, Dec. 11, 2025 /PRNewswire/ -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) ("Atossa" or the "Company"), a clinical-stage biopharmaceutical company developing novel therapies in oncology a...
Themefolio
Profiler
Peergroup
© PR Newswire
11.12.2025
DVA
LISTED
NYSE
DaVita Names New Leaders to Accelerate Care Transformation
News Preview
Appointments of Chief People Officer and Chief Strategy Officer underscore commitment to innovation and people-first approachDENVER, Dec. 11, 2025 /PRNewswire/ -- DaVita, a leading provider of kidney care services, today announced two key additions to its executive leadership team: Stephanie Hendrickson has been named Chief People Officer (CPO) an...
Themefolio
Profiler
Peergroup
© Globe Newswire
11.12.2025
MAIA
LISTED
XASE
MAIA Biotechnology Announces First Patient Dosed in THIO-104 Phase 3 Pivotal Trial Evaluating Ateganosine as Third-Line Treatment for Advanced Non-Small Cell Lung Cancer
News Preview
Key milestone achieved as Company advances clinical program to full approval trial of ateganosine sequenced with a checkpoint inhibitor in comparison to chemotherapy...
Themefolio
Profiler
Peergroup
© Globe Newswire
11.12.2025
NOTV
LISTED
NASDAQ
Inotiv Partners with VUGENE to Advance AI-Driven Drug Discovery and Bioinformatics Capabilities
News Preview
WEST LAFAYETTE, Ind., Dec. 11, 2025 (GLOBE NEWSWIRE) -- Inotiv, Inc. (NASDAQ: NOTV) (the “Company”, or “Inotiv”), a leading Contract Research Organization (CRO) specializing in nonclinical and analytical drug discovery and development services and research models and related products and services, and VUGENE, a multi-omics data analysis company p...
Themefolio
Profiler
Peergroup
© Newsfile
11.12.2025
BETR
LISTED
CSE
BetterLife Pharma Announces Engagement with Shanghai-Based YAFO Capital
News Preview
Vancouver, British Columbia--(Newsfile Corp. - December 11, 2025) - BetterLife Pharma Inc. (CSE: BETR) (OTCQB: BETRF) (FSE: NPAU) ("BetterLife" or the "Company"), an emerging biotech company focused on development of BETR-001, its proprietary non-hallucinogenic derivative of lysergic acid diethylamide ("LSD"), is pleased to announce...
Themefolio
Profiler
Peergroup
© BusinessWire
11.12.2025
ATRC
LISTED
NASDAQ
AtriCure Announces the First Patients Treated with Novel Dual Energy Platform
News Preview
AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative pain management, today announced successful first-in-human treatments using its novel dual energy platform that integrates Pulsed Field Ablation (PFA) with Advanced Radiof...
Themefolio
Profiler
Peergroup
© BusinessWire
11.12.2025
CRL
LISTED
NYSE
Charles River Extends Commitment to Advanced Therapy Developers with Second Incubator Program Cohort
News Preview
Charles River Laboratories International, Inc. (NYSE: CRL) today announced the second cohort of its Cell & Gene Therapy Incubator Program (CIP). Launched in December 2024, with the inaugural cohort announced in April 2025, the program provides early-stage biotechnology pioneers with access to extensive scientific and commercial expertise, as w...
Themefolio
Profiler
Peergroup
© PR Newswire
11.12.2025
INTS
LISTED
NASDAQ
Intensity Therapeutics, Inc. to Present Two Posters at the 2025 San Antonio Breast Cancer Symposium
News Preview
Poster PS5-08-16 Reports Early Observations from the INVINCIBLE-4 Study, an Ongoing Randomized, Presurgical Phase 2 Clinical Trial for Triple Negative Breast Cancer continue to show favorable safety 50% fewer grade 3 or higher Adverse Events were observed in the INT230-6 cohort compared to the Standard of Care ("SOC") neoadjuvant chemotherapy alon...
Themefolio
Profiler
Peergroup
© ACCESSWIRE
11.12.2025
TTNP
LISTED
NASDAQ
Black Titan Announces DAT+ Liquidity and Operational Readiness Pillar to Support Institutional-Grade Digital Asset Engagement
News Preview
NEW YORK, NY / ACCESS Newswire / December 11, 2025 / Black Titan Corporation (NASDAQ:BTTC) released the fifth pillar of its DAT+ framework, outlining the liquidity and operational criteria used to assess digital assets within an institutional environment.This pillar emphasizes:deep, stable liquidity across reliable venues,clear on-chain transaction...
Themefolio
Profiler
Peergroup
© Globe Newswire
11.12.2025
OKYO
LISTED
LSE
OKYO Pharma Announces New Data Showing Favorable Corneal Nerve Outcomes in Phase 2 Study for Neuropathic Corneal Pain
News Preview
LONDON and NEW YORK, Dec. 11, 2025 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative therapies for the treatment of neuropathic corneal pain, a severe ocular condition without an FDA approved therapy, is pleased to announce new analyses of corneal images from the recently comp...
Themefolio
Profiler
Peergroup
© Globe Newswire
11.12.2025
AIAI
LISTED
CSE
NetraMark Continues Expansion Into Phase 3 Programs With Contract From Global Biopharmaceutical Company
News Preview
TORONTO, Dec. 11, 2025 (GLOBE NEWSWIRE) -- NetraMark Holdings Inc. (the “Company” or “NetraMark”) (CSE: AIAI) (OTCQB: AINMF) (Frankfurt: PF0), a premier artificial intelligence (AI) company transforming clinical trials with AI-powered precision analytics in the pharmaceutical industry, today announced that it has been awarded a new contract by a...
Themefolio
Profiler
Peergroup
© Globe Newswire
11.12.2025
CVKD
LISTED
NASDAQ
Cadrenal Therapeutics Acquires VLX-1005, a First-in-Class Phase 2 12-LOX Inhibitor for Patients with Heparin-Induced Thrombocytopenia (HIT)
News Preview
PONTE VEDRA, Fla., Dec. 11, 2025 (GLOBE NEWSWIRE) -- Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a biopharmaceutical company developing transformative therapeutics to overcome the limitations of current anticoagulation therapy, today announced the acquisition of VLX-1005 and related 12-lipoxygenase (12-LOX) assets from Veralox Therapeutics (“Ver...
Themefolio
Profiler
Peergroup
© Globe Newswire
11.12.2025
SXTP
LISTED
NASDAQ
60 Degrees Pharmaceuticals Announces Expansion of ARAKODA® Sales and Marketing in 2026
News Preview
60 Degrees Pharmaceuticals will expand ARAKODA sales in 2026 with more reps, a GoodRx partnership, enhanced digital marketing, and added babesiosis trials...
Themefolio
Profiler
Peergroup
© Globe Newswire
11.12.2025
SYK
LISTED
NYSE
Stryker declares an $0.88 per share quarterly dividend
News Preview
Portage, Michigan, Dec. 11, 2025 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) announced that its Board of Directors has declared a quarterly dividend of $0.88 per share payable January 30, 2026, to shareholders of record at the close of business on December 31, 2025, representing an increase of 4.8% versus the prior year and previous quarter. ...
Themefolio
Profiler
Peergroup
© Globe Newswire
11.12.2025
MAIA
LISTED
XASE
MAIA Leadership Continues Insider Buying in 2025 and Trial Data Signals Breakout Potential
News Preview
CHICAGO, Dec. 11, 2025 (GLOBE NEWSWIRE) -- A recent round of open-market purchases marks another display of confidence as the small molecule telomere-targeting cancer therapy by MAIA Biotechnology, Inc. (NYSE American: MAIA) advances through mid- to late-stage clinical development. Newly filed disclosures show that CEO Dr. Vlad Vitoc and other bo...
Themefolio
Profiler
Peergroup
© Globe Newswire
11.12.2025
STEX
LISTED
NASDAQ
Streamex Corp. (NASDAQ: STEX) Acquires 9.9% Strategic Equity Stake in Royalty and Streaming Firm Empress Royalty Corp. Through a Premium Priced Share-for-Share Transaction at US$5.00 STEX with a Leading Institutional Investment Firm
News Preview
LOS ANGELES, Dec. 11, 2025 (GLOBE NEWSWIRE) -- Streamex Corp. (“Streamex” or the “Company”) (NASDAQ: STEX), a leader in institutional-grade tokenization and real-world asset infrastructure, today announced that it has acquired a 9.9% equity interest in Empress Royalty Corp. (“Empress”) (TSXV: EMPR) through a strategic share purchase from Terra Ca...
Themefolio
Profiler
Peergroup
© Globe Newswire
11.12.2025
ALGS
LISTED
NASDAQ
Aligos Therapeutics Presents Positive Data at HEP-DART 2025
News Preview
Oral presentation of ALG-055009 in vivo nonclinical data showcases synergistic fat mass loss in combination with incretin receptor agonists Oral presentation of ALG-055009 in vivo nonclinical data showcases synergistic fat mass loss in combination with incretin receptor agonists...
Themefolio
Profiler
Peergroup
© Globe Newswire
11.12.2025
ABSI
LISTED
NASDAQ
Absci Reports New Human Ex Vivo Data Demonstrating That ABS-201™ Stimulates Hair Growth and Regenerates Stem Cell Niche to Potentially Reverse Follicle Miniaturization
News Preview
Inhibiting prolactin receptor (PRLR) signaling with the ABS-201 anti-PRLR antibody promotes human hair follicle growth ex vivo...
Themefolio
Profiler
Peergroup
© Globe Newswire
11.12.2025
PRAX
LISTED
NASDAQ
Praxis Precision Medicines Announces Plans to File an NDA for Relutrigine in SCN2A and SCN8A Developmental and Epileptic Encephalopathies in Early 2026
News Preview
EMBOLD data to serve as basis of efficacy and safety following discussion with the FDA EMBOLD data to serve as basis of efficacy and safety following discussion with the FDA...
Themefolio
Profiler
Peergroup
© Globe Newswire
11.12.2025
GERN
LISTED
NASDAQ
Geron Corporation Announces Strategic Restructuring Plan to Position the Company for Long-Term Value Creation
News Preview
Restructuring Supports RYTELO® U.S. Commercial Strategy and Investment in Clinical Development...
Themefolio
Profiler
Peergroup
© BusinessWire
11.12.2025
ALNY
LISTED
NASDAQ
Alnylam Announces Partial Repurchase of 1.00% Convertible Senior Notes Due 2027
News Preview
Alnylam Pharmaceuticals, Inc. (“Alnylam”) (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it has entered into separate, privately negotiated repurchase agreements with certain holders of its 1.00% Convertible Senior Notes due 2027 (the “Notes”) to repurchase for cash (the “Repurchases”) approximately $34.4 million aggre...
Themefolio
Profiler
Peergroup
© BusinessWire
11.12.2025
SRPT
LISTED
NASDAQ
Sarepta Therapeutics Announces Refinancing of Approximately $291 Million of 1.25% Convertible Senior Notes due 2027
News Preview
Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that it has entered into separate, privately negotiated exchange agreements with a limited number of holders of its 1.25% convertible senior notes due 2027 (the “Existing Convertible Notes”). Pursuant to the exchange agreements, th...
Themefolio
Profiler
Peergroup
© BusinessWire
11.12.2025
STAA
LISTED
NASDAQ
Broadwood Partners Comments on STAAR Surgical Board Dissent on the Revised Sale to Alcon
News Preview
Broadwood Partners, L.P. and its affiliates (collectively, “Broadwood,” “we,” “us” or “our”) today reacted to the proxy statement supplement filed by STAAR Surgical Company (“STAAR” or the “Company”) (NASDAQ: STAA) with respect to the proposed acquisition of the Company by Alcon Inc. (“Alcon”) (NYSE: ALC). In addition, Broadwood released a new pre...
Themefolio
Profiler
Peergroup
© BusinessWire
11.12.2025
BMY
LISTED
NYSE
U.S. Food and Drug Administration (FDA) Grants Priority Review to Bristol Myers Squibb's Application for Opdivo® (nivolumab) Plus Chemotherapy Combination for Classical Hodgkin Lymphoma
News Preview
Bristol Myers Squibb (NYSE: BMY) today announced that the U.S. Food and Drug Administration (FDA) has accepted and granted priority review to the supplemental Biologics License Application (sBLA) for Opdivo® (nivolumab) in combination with doxorubicin, vinblastine and dacarbazine (AVD) for adult and pediatric (12 years and older) patients with pre...
Themefolio
Profiler
Peergroup
© Globe Newswire
11.12.2025
867
LISTED
HKSE
CMS (867/8A8): NDA of Innovative Drug Y-3 for Injection for Acute Ischemic Stroke Accepted in China
News Preview
SHENZHEN, CHINA, Dec. 11, 2025 (GLOBE NEWSWIRE) -- China Medical System Holdings Limited (the “Group” or “CMS”) is pleased to announce that on 11 December 2025, the New Drug Application (NDA) of Class 1 Innovative Drug Y-3 for Injection (proposed English generic name: Loberamisal for Injection) (“Y-3 for Injection” or the “Product”) has been acce...
Themefolio
Profiler
Peergroup
© Globe Newswire
11.12.2025
ROIV
LISTED
NASDAQ
Roivant Highlights Continued Pipeline Progress and Outlook for Company’s Next Phase of Growth at 2025 Investor Day
News Preview
BASEL, Switzerland and LONDON and NEW YORK, Dec. 11, 2025 (GLOBE NEWSWIRE) -- Roivant (Nasdaq: ROIV) today is hosting an Investor Day in New York City. Roivant leadership will highlight key pipeline updates and provide an update on the Company’s strategy for long-term value creation....
Themefolio
Profiler
Peergroup
© Globe Newswire
11.12.2025
RYTM
LISTED
NASDAQ
Rhythm Pharmaceuticals Announces Preliminary Data from Exploratory Phase 2 Trial that showed Setmelanotide Demonstrated Positive Efficacy Signal in Prader-Willi Syndrome
News Preview
-- BMI and hyperphagia reductions have been observed in patients with PWS treated with setmelanotide at Month 3 (n=8) and Month 6 (n=5); 17 of 18 enrolled patients remain on therapy -- -- Promising results supportive of Phase 3, registrational trial of setmelanotide in PWS --...
Themefolio
Profiler
Peergroup
© Globe Newswire
11.12.2025
ABEO
LISTED
NASDAQ
Abeona Therapeutics® Announces New Qualified Treatment Center for ZEVASKYN® in Texas
News Preview
CLEVELAND, Dec. 11, 2025 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced activation of The University of Texas Medical Branch (UTMB) in Galveston, Texas, as the newest Qualified Treatment Center (QTC) for the administration of ZEVASKYN (prademagene zamikeracel) gene-modified cellular sheets. ZEVASKYN, a first-of-its-ki...
Themefolio
Profiler
Peergroup
© ACCESSWIRE
11.12.2025
MAJI
LISTED
OTC
Exousia Pro, Inc. Announces Executed LOI for Strategic Acquisition of High-Revenue Telehealth Platform to Accelerate Nutraceutical Commercialization
News Preview
ORLANDO, FL / ACCESS Newswire / December 11, 2025 / Exousia Pro, Inc. (OTCID:MAJI), a clinical-stage biotechnology company focused on proprietary exosome-based delivery systems, is excited to announce that it has executed a Letter of Intent to acquire a high-growth, established telehealth organization. Once acquired the Telehealth Platform will ope...
Themefolio
Profiler
Peergroup
© ACCESSWIRE
11.12.2025
TTNP
LISTED
NASDAQ
Black Titan Introduces DAT+ Collaborative Engagement Pillar to Support High-Value Decentralized Ecosystems
News Preview
NEW YORK, NY / ACCESS Newswire / December 11, 2025 / Black Titan Corporation (NASDAQ:BTTC) announced the fourth pillar of its DAT+ initiative, outlining a framework for structured collaboration with decentralized projects demonstrating technical strength and long-term potential.The Company may consider partnership elements such as:providing insight...
Themefolio
Profiler
Peergroup
© Globe Newswire
11.12.2025
BYSI
LISTED
NASDAQ
BeyondSpring Announces New Analyses of DUBLIN-3 Phase 3 Study Showing Survival Benefit of Plinabulin + Docetaxel in Post Anti-PD-(L)1 for Non-squamous EGFR WT NSCLC and a Reduction in Brain Metastasis Compared to Docetaxel at NACLC 2025
News Preview
FLORHAM PARK, N.J., Dec. 11, 2025 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ: BYSI), a clinical-stage biopharmaceutical company developing first-in-class immune-modulating cancer therapies, today announced new post-hoc analyses from its global Phase 3 DUBLIN-3 Study (Lancet Resp Med 12:775, 2024), showing that Plinabulin plus docetaxel provide...
Themefolio
Profiler
Peergroup
© Globe Newswire
11.12.2025
KYMR
LISTED
NASDAQ
Kymera Therapeutics Announces U.S. FDA Fast Track Designation for KT-621, a First-in-Class, Oral STAT6 Degrader for the Treatment of Atopic Dermatitis
News Preview
Fast Track designation supported by positive results from the KT-621 BroADen Phase 1b atopic dermatitis (AD) patient trial ...
Themefolio
Profiler
Peergroup
© Globe Newswire
11.12.2025
CNTA
LISTED
NASDAQ
Centessa Pharmaceuticals Announces CEO Transition as Company Advances Strategy to Extend Orexin Leadership into Multiple Neuroscience Indications
News Preview
Mario Alberto Accardi PhD, President and founder of Centessa’s Orexin Program, appointed Chief Executive Officer and member of the Board of Directors Mario Alberto Accardi PhD, President and founder of Centessa’s Orexin Program, appointed Chief Executive Officer and member of the Board of Directors...
Themefolio
Profiler
Peergroup
© Globe Newswire
11.12.2025
CBUS
LISTED
NASDAQ
Cibus Welcomes the Positive Conclusion of Trilogue Negotiations on New Genomic Techniques Legislation Between the European Parliament and Council
News Preview
Political agreement on New Genomic Techniques (NGTs), including gene editing, advances a science-based path for plant breeding innovation and supports Cibus’ plans to bring improved traits to European growers...
Themefolio
Profiler
Peergroup
Long/Short | Fractionals | Margin | Hedge · 4 powerful Trading App | MT4.MT5.ACTIVTRADER | TradingViewplus
More information, click here
More sector specific news
Your Press Release is missing or you want share news over GICS11? Drop us a line.
